Drishti Discoveries

Drishti Discoveries is an early-stage biotech integrating AI-driven target discovery with a patented artificial miRNA gene therapy platform to treat neurodegenerative diseases. The company's core technology is designed for highly efficient and specific modulation of target RNA expression, aiming to create durable one-time treatments. Currently in the pre-clinical stage, Drishti is positioned in the high-need but challenging neurology space, competing with other genetic medicine approaches. Its success hinges on validating its platform and advancing its lead programs into clinical development.

Proprietary artificial microRNA (miRNA) platform delivered via gene therapy vectors for sustained, targeted knockdown of gene expression in the nervous system. Utilizes a scaffold-specific AI algorithm for optimal therapeutic sequence design.

Drishti competes in the crowded neurological gene therapy and RNA-targeting space, which includes companies like Voyager Therapeutics, UniQure, and Brain Neurotherapy Bio, as well as RNAi leaders like Alnylam and antisense specialists like Ionis Pharmaceuticals. Differentiation will require demonstrating superior delivery, durability, or safety profile compared to existing modalities.